Highlights
In this retrospective analysis, patients with myelodysplastic neoplasms (MDS) with isolated del(5q) and TP53 multihit alterations had markedly better overall survival and slower acute myeloid leukemia (AML) progression than patients with other low-blast TP53-multihit MDS.
The reported median overall survival was 70.2 months for MDS-del(5q) TP53 multihit versus 13.9 months for low-blast MDS TP53 multihit without isolated del(5q), with corresponding times to AML progression of 31.9 versus 7.2 months.
Patients with isolated del(5q) and TP53 multihit also differed biologically and clinically, showing higher platelet counts, more frequent SF3B1 mutations, and lower risk assignment by IPSS-R and IPSS-M.
These findings argue that TP53 multihit status, although adverse, may not carry uniform prognostic weight across all MDS genomic contexts and should not automatically override the distinct biology of isolated del(5q).
Background
Classification of MDS has moved steadily from morphology-based taxonomies toward genomically informed disease definitions. This shift has been especially important for two entities with strong prognostic implications: MDS with isolated del(5q), historically associated with a relatively favorable clinical course, and MDS with biallelic or “multihit” TP53 alterations, which is consistently linked to treatment resistance, genomic instability, rapid leukemic transformation, and poor survival.
Under modern classification systems, isolated del(5q) is recognized as a distinct MDS subtype, but the favorable-risk designation is contingent on the absence of biologically dominant high-risk features, particularly TP53 multihit alterations. At the same time, TP53-mutated MDS is increasingly understood as a genomically defined high-risk disease state, especially when the TP53 lesion is multihit rather than monoallelic. In practice, this creates a classification tension: when isolated del(5q) and TP53 multihit coexist, which feature should dominate disease labeling and prognostic interpretation?
This question matters clinically. Isolated del(5q) often presents with anemia, preserved or elevated platelet counts, and characteristic megakaryocytic dysplasia, and many patients derive benefit from lenalidomide. By contrast, TP53 multihit disease commonly co-segregates with complex cytogenetics and conveys poor outcomes even with hypomethylating agents or transplant. If the prognosis of del(5q) with TP53 multihit resembles conventional TP53-multihit MDS, then these cases should arguably be grouped with TP53-defined high-risk disease. If, however, del(5q) modifies the adverse effect of TP53 multihit, then a separate conceptual and diagnostic approach may be justified.
The study by Montoro and colleagues directly addresses this unresolved issue by comparing patients with MDS with isolated del(5q) and TP53 multihit alterations against a reference cohort of low-blast MDS with TP53 multihit but without isolated del(5q).
Proposed Section Structure for This Topic
For a clinically oriented interpretation of this paper, the most logical structure is: clinical context and classification problem; study design and comparator groups; key clinicogenomic findings; outcome analysis; implications for disease classification; limitations and remaining uncertainties; and a practice-focused conclusion. This structure is used below because the main value of the paper lies not only in its data but also in how those data challenge current diagnostic framing.
Study Design
Montoro et al conducted a retrospective analysis of patients with MDS with isolated del(5q) harboring TP53 multihit alterations, here referred to as MDS-del(5q) TP53 multihit. This group was compared with patients with low-blast MDS with TP53 multihit alterations and without isolated del(5q), referred to as MDS-LB TP53 multihit.
The study included 43 patients in the MDS-del(5q) TP53 multihit cohort and 68 patients in the MDS-LB TP53 multihit comparator cohort. The principal outcomes were overall survival and time to AML progression. The investigators also compared baseline clinical and molecular characteristics, including blood counts, mutational co-landscape, and assignment under prognostic scoring systems such as IPSS-R and IPSS-M.
Because the study focused specifically on TP53 multihit status, it addresses a biologically meaningful subgroup rather than simply TP53 mutation positivity. This is important: a single TP53 mutation does not carry the same prognostic significance as multihit in MDS, and current evidence strongly supports distinction between monoallelic and biallelic or functionally equivalent TP53 disruption.
Key Findings
Distinct clinical phenotype despite shared TP53 multihit status
The del(5q) TP53-multihit cohort did not merely represent a cytogenetic subset of otherwise similar high-risk MDS. Instead, these patients retained several features more typical of classical del(5q) disease. They had significantly higher platelet counts and more frequent SF3B1 mutations than the non-del(5q) TP53-multihit group. They were also less often categorized as high-risk by IPSS-R or IPSS-M.
These observations suggest that the biology of isolated del(5q) continues to shape disease behavior even when TP53 is severely altered. The coexistence of SF3B1 mutations is particularly noteworthy because it points toward a broader molecular context that may differ from canonical TP53-driven complex-karyotype MDS. In other words, the adverse TP53 genotype may be operating within a less aggressive or at least biologically distinct substrate.
Overall survival was substantially longer in del(5q) TP53 multihit disease
The most practice-relevant result was the large survival separation between groups. Median overall survival was 70.2 months in MDS-del(5q) TP53 multihit versus 13.9 months in MDS-LB TP53 multihit. For a TP53-multihit cohort, a survival beyond 5 years is striking and sharply contrasts with the generally poor outcomes expected in TP53-defined MDS.
This finding does not imply that TP53 multihit is benign in isolated del(5q). Rather, it suggests that its negative prognostic effect is attenuated in this setting compared with other low-blast TP53-multihit MDS. Clinically, that distinction is crucial. A biomarker can remain adverse without being universally determinative across all genomic contexts.
AML progression was delayed relative to other TP53-multihit MDS
The same pattern was seen for leukemic evolution. Time to AML progression was 31.9 months in MDS-del(5q) TP53 multihit versus 7.2 months in MDS-LB TP53 multihit. This fourfold-plus difference reinforces the idea that isolated del(5q) modifies the natural history of TP53-multihit disease.
AML transformation is among the most clinically meaningful events in MDS, influencing surveillance intensity, transplant timing, and treatment choice. A prolonged pre-AML interval may allow more deliberate management and may affect how aggressively clinicians pursue early allogeneic transplantation in selected patients.
The prognostic advantage persisted beyond the effect of complex karyotype
One possible explanation for the inferior outcomes of the comparator group would be enrichment for complex karyotype, a known adverse feature frequently intertwined with TP53 multihit alterations. The authors therefore performed a clinically important comparison against MDS-LB TP53 multihit cases without complex karyotype.
Even with that restriction, the del(5q) TP53-multihit group continued to fare better. Median overall survival was 70.2 months versus 39.9 months, and time to AML progression was 31.9 months versus 11.4 months. This analysis strengthens the central conclusion that isolated del(5q) is not simply a proxy for lesser cytogenetic complexity. Instead, it appears to confer a biologically distinct disease trajectory.
Why these results matter for classification
Current classification frameworks tend to treat TP53 multihit disease as a high-risk category with broad prognostic consistency across presentations. The present study challenges the assumption that all TP53-multihit MDS behaves similarly. If patients with isolated del(5q) and TP53 multihit live substantially longer and transform later than other TP53-multihit patients, then a uniform classification approach may obscure clinically relevant heterogeneity.
This does not necessarily mean these cases should be folded back into conventional favorable-risk MDS with del(5q). The prognosis is likely still worse than for isolated del(5q) without TP53 multihit, and clinicians should remain cautious. However, the data argue against reflexively equating this subgroup with the very poor-risk biology of non-del(5q) TP53 multihit MDS.
Interpretation and Clinical Relevance
The study’s central message is that genomic context matters. TP53 multihit status is among the most powerful adverse determinants in myeloid neoplasia, but its effect is not biologically isolated from the rest of the genome and karyotype. In isolated del(5q), the disease may arise through a pathway that retains some of the clinicopathologic characteristics and relatively indolent tempo of the del(5q) phenotype, even after acquisition of high-risk TP53 events.
For hematologists, this raises several practical implications. First, diagnosis and risk communication should be nuanced. A report of TP53 multihit in a patient with isolated del(5q) should certainly trigger concern, but the expected trajectory may not mirror that of classic TP53-multihit complex-karyotype MDS. Second, treatment planning may need to account for this intermediate biology. Such patients may still be candidates for disease-modifying therapy and transplant evaluation, yet prognostic conversations should not rely solely on data from mixed TP53-multihit populations.
Third, the findings reinforce the value of integrated pathology. Cytogenetics, molecular profiling, marrow morphology, and clinical phenotype all matter. A simplified one-marker approach risks both overclassification and undertreatment or overtreatment. In this respect, the paper is less about downgrading TP53 and more about improving precision.
How Might These Cases Be Classified?
Based on the available data, the most defensible position is that MDS with isolated del(5q) and TP53 multihit alterations should be recognized as a distinct high-risk variant within the del(5q) spectrum rather than being automatically merged with all other TP53-multihit MDS. This framing preserves two truths simultaneously: TP53 multihit is clinically adverse, and isolated del(5q) still appears to modulate that risk.
A taxonomy that entirely excludes such cases from the del(5q) family may fail to reflect their phenotype, mutational associations, and outcome differences. Conversely, labeling them simply as favorable-risk del(5q) would clearly be misleading. The data support a middle position: biologically del(5q)-defined, but prognostically upgraded because of TP53 multihit.
Whether future WHO or International Consensus Classification updates will formalize such a subcategory remains uncertain, but studies like this one provide the empirical basis for doing so. At minimum, pathology reports and multidisciplinary discussions should make explicit that TP53 multihit in isolated del(5q) does not appear prognostically equivalent to TP53 multihit in the broader low-blast MDS population.
Limitations
Several cautions are warranted. The study was retrospective, which introduces unavoidable selection bias and treatment heterogeneity. The sample size, although notable for such a rare subgroup, remained modest at 43 patients in the key del(5q) TP53-multihit cohort. The abstract does not provide hazard ratios, confidence intervals, or detailed adjustment methods, which limits a more granular assessment of effect size and independence from confounders.
Another limitation is that the treatment exposures are not summarized in the abstract. Outcomes in del(5q) disease can be influenced by prior or subsequent use of lenalidomide, hypomethylating agents, supportive care intensity, and transplant. Without detailed treatment stratification, one cannot fully separate biology from management effects. Likewise, the exact definition of TP53 multihit, while likely aligned with current molecular standards, is not detailed in the abstract and may affect reproducibility across laboratories.
Finally, this analysis establishes relative rather than absolute prognosis. The key comparator was other low-blast TP53-multihit MDS, not isolated del(5q) lacking TP53 multihit. Therefore, the study answers whether these patients fare better than other TP53-multihit MDS, but not exactly how much worse they fare than classical isolated del(5q).
Expert Commentary
The broader literature strongly supports TP53 allelic state as a major determinant of outcome in MDS. Seminal work has shown that multi-hit TP53 abnormalities, rather than TP53 mutation per se, drive the worst prognosis and closely associate with complex karyotype and genomic instability. At the same time, disease-defining lesions such as del(5q), SF3B1 mutations, and ring sideroblast biology are known to create distinct clinical phenotypes. The current study sits at the intersection of these ideas and suggests that one adverse genotype does not completely erase lineage-defining biologic context.
From a translational perspective, this is plausible. Del(5q) MDS has characteristic haploinsufficiency-driven biology involving genes on chromosome 5q and a recognizable hematopoietic phenotype. TP53 multihit may accelerate progression within this framework without fully converting the disease into the archetypal TP53-multihit state seen in complex-karyotype MDS. That hypothesis needs prospective validation but fits the observed clinicogenomic differences.
Conclusion
The study by Montoro et al provides persuasive evidence that MDS with isolated del(5q) and TP53 multihit alterations behaves better than other low-blast TP53-multihit MDS, with longer survival and delayed AML progression. These data challenge any classification scheme that treats all TP53-multihit MDS as prognostically homogeneous.
For clinicians and diagnosticians, the practical takeaway is straightforward: TP53 multihit remains an adverse finding in isolated del(5q), but it does not appear to abolish the distinct biology and partial prognostic advantage of the del(5q) context. This subgroup likely deserves separate recognition in risk assessment, pathology reporting, and future classification updates.
Prospective studies with uniform molecular definitions, treatment annotation, and comparison against TP53-wild-type isolated del(5q) will be essential to refine management. Until then, integrated interpretation rather than single-marker determinism remains the best approach.
Funding and ClinicalTrials.gov
The PubMed record and abstract provided do not specify funding details. This was a retrospective observational study, and no ClinicalTrials.gov registration is apparent from the available citation information.
References
1. Montoro MJ, Acha P, Haferlach C, Chan O, Navarro V, Kubota Y, Schulz F, Briski R, Al Ali NH, Xicoy B, Palomo L, López-Cadenas F, Bosch F, Meggendorfer M, González T, Eder LN, Jerez A, Wang Y, Campagna A, Betz B, Santini V, Bernal T, Such E, Platzbecker AS, Kewan T, Gurnari C, Zindel C, Kulasekararaj A, Voso MT, Sekeres M, Díaz-Varela N, Al-Kali A, Polini A, Diral E, Memoli M, Platzbecker U, Haase D, Zeidan AM, Díez-Campelo M, Garcia-Manero G, Wiseman DH, Della Porta MG, Germing U, Maciejewski J, Komrokji RS, Solé F, Haferlach T, Fenaux P, Valcárcel D. How should myelodysplastic neoplasms with isolated deletion 5q and TP53 multihit alterations be classified? Leukemia. 2026-04-30. PMID: 42062555.
2. Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, Yoshizato T, Shiozawa Y, Saiki R, Malcovati L, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26(10):1549-1556.
3. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200-1228.
4. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703-1719.
5. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, Te Boekhorst P, Sanz G, Del Cañizo C, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118(14):3765-3776.
